Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Emergence of a novel extended-spectrum-β-lactamase (ESBL)-producing, fluoroquinolone-resistant clone of extraintestinal pathogenic Escherichia coli in Kumasi, Ghana.

Feglo P, Adu-Sarkodie Y, Ayisi L, Jain R, Spurbeck RR, Springman AC, Engleberg NC, Newton DW, Xi C, Walk ST.

J Clin Microbiol. 2013 Feb;51(2):728-30. doi: 10.1128/JCM.03006-12. Epub 2012 Dec 12. No abstract available.

2.

Genetic background of Escherichia coli and extended-spectrum beta-lactamase type.

Branger C, Zamfir O, Geoffroy S, Laurans G, Arlet G, Thien HV, Gouriou S, Picard B, Denamur E.

Emerg Infect Dis. 2005 Jan;11(1):54-61.

3.

Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamase-producing E. coli in Japan.

Matsumura Y, Yamamoto M, Higuchi T, Komori T, Tsuboi F, Hayashi A, Sugimoto Y, Hotta G, Matsushima A, Nagao M, Takakura S, Ichiyama S.

Int J Antimicrob Agents. 2012 Aug;40(2):158-62. doi: 10.1016/j.ijantimicag.2012.04.013. Epub 2012 Jun 27.

PMID:
22743014
4.

Identification of fluoroquinolone-resistant extended-spectrum β-lactamase (CTX-M-8)-producing Escherichia coli ST224, ST2179 and ST2308 in buffalo (Bubalus bubalis).

Aizawa J, Neuwirt N, Barbato L, Neves PR, Leigue L, Padilha J, Pestana de Castro AF, Gregory L, Lincopan N.

J Antimicrob Chemother. 2014 Oct;69(10):2866-9. doi: 10.1093/jac/dku218. Epub 2014 Jun 13. No abstract available.

PMID:
24928853
6.

The revolving door between hospital and community: extended-spectrum beta-lactamase-producing Escherichia coli in Dublin.

Burke L, Humphreys H, Fitzgerald-Hughes D.

J Hosp Infect. 2012 Jul;81(3):192-8. doi: 10.1016/j.jhin.2012.04.021. Epub 2012 Jun 2.

PMID:
22658893
7.

Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.

Ortega M, Marco F, Soriano A, Almela M, Martínez JA, Muñoz A, Mensa J.

J Antimicrob Chemother. 2009 Mar;63(3):568-74. doi: 10.1093/jac/dkn514. Epub 2009 Jan 6.

PMID:
19126669
8.

Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO.

Clin Infect Dis. 2001 Oct 15;33(8):1288-94. Epub 2001 Sep 14.

PMID:
11565067
9.

Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.

Yokota S, Sato T, Okubo T, Ohkoshi Y, Okabayashi T, Kuwahara O, Tamura Y, Fujii N.

Chemotherapy. 2012;58(1):52-9. doi: 10.1159/000336129. Epub 2012 Feb 15.

PMID:
22343392
10.

Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates.

Sorlozano A, Gutierrez J, Jimenez A, de Dios Luna J, Martínez JL.

J Clin Microbiol. 2007 Aug;45(8):2740-2. Epub 2007 Jun 13.

11.

Isolation of fluoroquinolone-resistant O25b:H4-ST131 Escherichia coli with CTX-M-14 extended-spectrum β-lactamase from UK river water.

Dhanji H, Murphy NM, Akhigbe C, Doumith M, Hope R, Livermore DM, Woodford N.

J Antimicrob Chemother. 2011 Mar;66(3):512-6. doi: 10.1093/jac/dkq472. Epub 2010 Dec 15.

PMID:
21172781
12.

Fluoroquinolone resistance in pediatric bloodstream infections because of Escherichia coli and Klebsiella species.

Kim JY, Lautenbach E, Chu J, Goyal M, Nachamkin I, McGowan K, Coffin S, Zaoutis T.

Am J Infect Control. 2008 Feb;36(1):70-3. doi: 10.1016/j.ajic.2007.01.012.

PMID:
18241740
13.

Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States.

Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV.

Chemotherapy. 2011;57(4):335-8. doi: 10.1159/000329661. Epub 2011 Sep 6.

PMID:
21912115
14.

Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment.

Pitout JD.

Expert Rev Anti Infect Ther. 2012 Oct;10(10):1165-76. doi: 10.1586/eri.12.110. Review.

PMID:
23199402
15.
16.

High prevalence of ST131 among CTX-M-producing Escherichia coli from community-acquired infections, in the Czech Republic.

Papagiannitsis CC, Študentová V, Jakubů V, Španělová P, Urbášková P, Žemličková H, Hrabák J.

Microb Drug Resist. 2015 Feb;21(1):74-84. doi: 10.1089/mdr.2014.0070. Epub 2014 Sep 4.

PMID:
25188031
17.

[In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum β-lactamase].

Villar HE, Jugo MB, Visser M, Hidalgo M, Hidalgo G, Maccallini GC.

Rev Esp Quimioter. 2014 Mar;27(1):51-5. Spanish.

18.

Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.

Baudry PJ, Nichol K, DeCorby M, Mataseje L, Mulvey MR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2008 May;52(5):1846-9. doi: 10.1128/AAC.01176-07. Epub 2008 Feb 25.

19.

Ciprofloxacin-resistant, CTX-M-15-producing Escherichia coli ST131 clone in extraintestinal infections in Italy.

Cerquetti M, Giufrè M, García-Fernández A, Accogli M, Fortini D, Luzzi I, Carattoli A.

Clin Microbiol Infect. 2010 Oct;16(10):1555-8. doi: 10.1111/j.1469-0691.2010.03162.x.

20.

Multi-drug resistant escherichia coli with extended-spectrum beta-lactamase activity and fluoroquinolone resistance isolated from clinical infections in dogs.

Warren A, Townsend K, King T, Moss S, O'Boyle D, Yates R, Trott DJ.

Aust Vet J. 2001 Sep;79(9):621-3. Review. No abstract available.

PMID:
11702934

Supplemental Content

Support Center